Compare Fabrinet (FN) vs Summit Therapeutics Inc (SMMT) Price & Performance

Fabrinet (FN) trades at $474.19, down 1.78% on the day, with a bearish technical signal despite strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.72 exceeding expectations. Analyst consensus remains strongly bullish with a $733 price target, though technical indicators show selling pressure with support at $473 and resistance at $484.

FN presents a compelling growth story driven by AI infrastructure demand, with revenue projected to grow from $3.42B to $4.2B in 2026. However, premium valuation metrics (P/E 41.81, P/B 7.57) and technical bearishness create near-term headwinds. The risk-reward favors long-term investors given the company's strategic positioning in optical communications and debt-free balance sheet.

Summit Therapeutics (SMMT) trades at $14.51, down 6.21% today, with a bearish technical outlook despite positive clinical trial results for its lung cancer drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, but maintains strong analyst support with 14 buy ratings and a $15.57 consensus price target. Recent developments include the $105 million divestiture of ridinilazole to Biossil and upcoming Q2 2026 earnings.

SMMT presents a high-risk, binary investment case centered on ivonescimab's commercial potential. While analyst sentiment is bullish and recent trial data is promising, the company's significant losses, cash burn, and single-asset focus pose substantial risks. The stock's volatility and concentrated ownership create potential for sharp moves around clinical and regulatory catalysts.